Working… Menu

Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01) (ABX067)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00625573
Recruitment Status : Completed
First Posted : February 28, 2008
Last Update Posted : September 18, 2009
Celgene Corporation
Information provided by:
Mt. Sinai Medical Center, Miami

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : February 2009
Actual Study Completion Date : March 2009
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 June 5, 2014
July 5, 2014